AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
Provided herein are compounds of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof described herein. Also provided herein are pharmaceutical compositions comprising a compound Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (I-A), (I-B), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.
1 . A compound of Formula (III-A):
or a pharmaceutically acceptable salt thereof wherein:
R 2 and R 3 are each independently —H, —C 1 -C 6 alkyl, —C 1 -C 6 fluoroalkyl, -halo, —CN, —OR 7 or —S(O)(Y)R 6 ,
Y is ═O or ═NH;
R 6 and R 7 are independently H, C 1 -C 6 alkyl, or C 1 -C 6 fluoroalkyl; and
the compound is not 5,8-dimethoxy-6-methyl-1,2,3,4-tetrahydronaphthalen-2-amine; 5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine; 6-bromo-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine; 7-bromo-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;
5,7,8-trimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine; or 5,6,8-trimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine.
2 . The compound of claim 1 , wherein at least one of R 2 and R 3 is —H.
3 . The compound of claim 1 , wherein R 2 and R 3 are each independently —H, —C 1 -C 6 alkyl, -halo, —CN, or —S(O)(Y)R 6 .
4 . The compound of claim 1 , wherein R 2 and R 3 are each independently —H, —S(O) 2 R 6 , or —S(O)(NH)R 6 .
5 . The compound of claim 4 , wherein R 6 is C 1 -C 6 alkyl.
6 . The compound of claim 1 , wherein R 2 and R 3 are each independently —H, -halo, —C 1 -C 6 alkyl, —S(O) 2 Me, —CN, or —S(O)(NH) Me.
7 . The compound of claim 1 , wherein R 2 and R 3 are each independently —H or -halo.
8 . The compound of claim 1 , wherein R 2 and R 3 are each independently —H or -Me.
9 . The compound of claim 1 , wherein R 2 and R 3 are each independently —H or —CN.
10 . The compound of claim 1 , wherein R 2 and R 3 are each independently —H or —S(O) 2 Me.
11 . The compound of claim 1 , wherein R 2 and R 3 are each independently —H or —S(O)(NH) Me.
12 . The compound of claim 1 , wherein R 2 and R 3 are each independently —H, —Cl, —F, or —I.
13 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
14 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
15 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
16 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
17 . The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof
18 . A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
19 . A method of treating a mental health disease or disorder, the method comprising administering a therapeutically effective amount of the composition of claim 18 .